Abstracts tagged "Cytotoxic Cells"

Abstract Number: 1735 • ACR Convergence 2022
Clonally Expanded Cytotoxic CD8+ T Cells Recognize Citrullinated Antigens in ACPA+ Rheumatoid Arthritis
Jae-Seung Moon¹, Shady Younis², Orr Sharpe², Navin Rao³, Julie Carman³, Eddie James⁴, Jane Buckner⁴, Kevin D Deane⁵, Michael Holers⁶, Laura Donlin⁷, Mark Davis² and William Robinson⁸, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁶Department of Medicine Division of Rheumatology, Aurora, CO, ⁷Hospital for Special Surgery, New York, NY, ⁸Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with MHC polymorphisms. The shared epitope polymorphism in MHC class II genes is by far…
Abstract Number: 1748 • ACR Convergence 2022
Deep Immune Profiling of Cytotoxic T Cells (CTL) from Patients with Ankylosing Spondylitis Revealed a Subset of CTL Co-Expressing PD-1 and TIGIT That Resists Immune Exhaustion
Michael Tang¹, Addison Pacheco², Zoya Qaiyum³, Melissa Lim¹ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Unresolved, chronic inflammation is a key feature of Ankylosing Spondylitis (AS) yet the immunological events perpetuating remain unclear. The strongest genetic association with AS…
Abstract Number: 0967 • ACR Convergence 2021
Antigen-specific and Bystander Autoreactive T Cell Control in Peripheral Blood of ACPA+ Rheumatoid Arthritis Patients Administered Antigen-specific Tolerising Immunotherapy
Pascale Wehr¹, Ranjeny Thomas², Nishta Ramnoruth³, Swati Patel³, Jamie Rossjohn⁴ and Hugh Reid⁴, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²University of Queensland, Diamantina Institute, Brisbane, Australia, ³University Of Queensland, Brisbane, Australia, ⁴Monash University, Melbourne, Australia
Background/Purpose: The control of autoreactive T cells in an antigen-specific manner in autoimmune diseases is a major clinical research goal. Various regulatory immune signatures have…
Abstract Number: 0993 • ACR Convergence 2021
The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
Mikel Gurrea-Rubio¹, Jeffrey Ruth¹, Qi Wu¹, Eliza Pei-Suen Tsou¹, Phillip Campbell¹, Peggy Randon¹, M.Asif Amin¹, Nora Singer², Feng Lin³ and David Fox¹, ¹University of Michigan, Ann Arbor, MI, ²The MetroHealth System, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The use of Immune Checkpoint Inhibitors (ICIs) is limited by the induction of immune-related adverse events. CD6 is expressed by most T lymphocytes and…
Abstract Number: 1772 • ACR Convergence 2021
Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial
Antoine Enfrein¹, Beatrice Clemenceau², Soraya Saiagh³, Céline Bressollette⁴, Zahir Amoura⁵, Henri Vie² and Mohamed Hamidou¹, ¹Médecine interne, CHU de Nantes, Nantes, France, ²Inserm U1232, Université de Nantes, Nantes, France, ³Unité de Thérapie Cellulaire et Génique, CHU de Nantes, Nantes, France, ⁴Laboratoire de Virologie, CHU de Nantes, Nantes, France, ⁵Médecine interne, Hôpital Pitié Salpêtrière, AP-HP, Paris, France
Background/Purpose: Epstein-Barr Virus (EBV) has been suggested as a potential environmental factor in systemic lupus erythematosus (SLE) onset and disease activity. Here, we report the…
Abstract Number: 1575 • ACR Convergence 2020
CD6 Is a Target for Cancer Immunotherapy
Jeffrey Ruth¹, Mikel Gurrea Rubio², Kalana Athukorala³, Stephanie Rasmussen¹, Weber Daniel¹, Peggy Randon¹, M Asif Amin¹, Phillip Campbell¹, Pei-suen Tsou¹, Yang Mao-Draayer¹, Qi Wu⁴, Matthew Lind¹, Rosemary Gedert¹, Thomas Lanigan¹, Venkateshwar Keshamouni¹, Nora Singer⁵, Feng Lin⁶ and David Fox⁷, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³University of Michigan, Ann Arbor, MN, ⁴University of Michigan, Ann Arbor, ⁵The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…
Abstract Number: 2047 • ACR Convergence 2020
Synovial CD8 T Cells in Rheumatoid Arthritis Exhibit High Antigen-independent Cytokine Production and Low Cytotoxic Potential
Anna Helena Jonsson¹, Fan Zhang², Emma Gomez-Rivas³, Karishma Rupani⁴, Gerald Watts⁵, Kevin Wei¹, Runci Wang⁴, Deepak Rao⁴, Accelerating Medicines Partnership (AMP) - RA/SLE⁶, Soumya Raychaudhuri² and Michael Brenner¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigam and Women's Hospital, Boston, ⁶., Boston
Background/Purpose: T cell-derived pro-inflammatory cytokines are major drivers of RA pathogenesis, and these cytokines have traditionally been attributed to CD4 T cells. However, single-cell RNA-sequencing…
Abstract Number: 0449 • ACR Convergence 2020
Cytotoxic T Cells with a Chronic Antigen Exposure Phenotype Drive Immune Checkpoint Inhibitor Sicca
Blake Warner¹, Billel Gasmi², David Kleiner³, Paola Perez Riveros⁴, Daniel Barber⁵, Shunsuke Sakai⁵ and Alan Baer⁶, ¹National Institute of Dental and Craniofacial Research, Bethesda, ²National Cancer Institute, Bethesda, MD, ³National Cancer Institute, Bethesda, ⁴National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁵National Institute of Allergy and Infectious Disease, Bethesda, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) have advanced the field of cancer therapeutics. By blocking the negative co-stimulation of T cells, ICI augment the anti-tumor immune…
Abstract Number: 0473 • ACR Convergence 2020
Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Mingce Zhang¹, Remy Cron², Devin Absher³, Prescott Atkinson¹, Winn Chatham¹ and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³HudsonAlpha Institute for Biotechnology, Huntsville, AL
Background/Purpose: Cytokine storm syndrome (CSS), also known as macrophage activation syndrome (MAS) or secondary hemophagocytic lymphohistiocytosis (HLH), is a life threatening condition that commonly presents…
Abstract Number: 0846 • ACR Convergence 2020
MHC Class I Epitopes Derived from Autoantibody Variable Regions, Conjugated to Synthetic Oligodeoxynuleotides, Induce Cytotoxic T Cells That Deplete Autoreactive B Cells and Ameliorate Murine Lupus
Ram Singh¹, ¹UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: B cell depletion or modulation is emerging as a major treatment modality for autoimmune diseases. However, the current treatments to accomplish this non-specifically target…
Abstract Number: 1443 • ACR Convergence 2020
High-dimensional Analyses of Checkpoint-inhibitor Related Arthritis Synovial Fluid Cells Reveal a Unique, Proliferating CD38hi Cytotoxic CD8 T Cell Population Induced by Type I IFN
Runci Wang¹, Karmela Kim Chan², Amy Cunningham-Bussel¹, Gregory Vitone³, Aidan Tirpack², Caroline Benson², Gregory Keras⁴, Anna Helena Jonsson⁵, Michael Brenner⁵, Laura Donlin⁶, Anne Bass⁷ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, ⁴Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, Weill Cornell Medicine, New York, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Checkpoint inhibitors (CI) used to treat cancer frequently trigger immune-related adverse events, including inflammatory arthritis. CI-related arthritis (CIrA) occurs in ~5% of treated patients,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].